C21 · Pharmaceuticals · China
Share of priority review drug approval applications treating cancer
China: 42.5% in 1 Jan 2020 to 20 Mar 2025.
- 42.5% Latest · China · 1 Jan 2020 to 20 Mar 2025
- Irregular Release cadence
- 1 Record · 1 region · 2020–2025
Verified 27 Sep 2026 · 1 publisher
The figure
One published observation so far. A chart follows as soon as a second period is published.
Every record
1 record · 1 region · 2020–2025. Each period links to its record: the value, its source evidence and original document.
| Period | Value | Source | Type |
|---|---|---|---|
| China 1 record | |||
| 1 Jan 2020 to 20 Mar 2025 | 42.5% | State Council · 20 Mar 2025 | |
Download this data
Every file carries its provenance: the CSV has a source column per row, and the chart images print the publisher, the licence and this page's address under the drawing. Source: State Council. Licence: CC BY 4.0.
Use and publication rights
- View, cite and link: free
Quote any number, cite this page or a single record, and link to it anywhere.
- Copy, chart and republish: free with attribution
The data is published under CC BY 4.0, commercial use included. Credit StatOrigin and the original publisher (State Council); the chart files already carry that line.
- The source documents: the publisher's terms
Figures are facts read from the publishers' own documents. The documents themselves, their text and design, stay under each publisher's terms; follow the source links for those.
How this measure is built
- Definition
- Percentage share of priority review drug approval applications targeting oncology indications.
- Measure
- One slice of Drug approval applications ( counting rule: priority review, form: share, segment: oncology ) . Total number of regulatory applications reviewed for drug marketing authorization. Region and period are columns on every record, not slices.
- Limitations
- Values are shown as published; StatOrigin does not revise, fill gaps or convert currencies.
- Verification
- Each value, unit, period and place was checked against its source evidence before publication. See the methodology and the corrections process.
Sources · 1 document
| Document | Publisher | Published | Data points |
|---|---|---|---|
| Measures facilitate approval of 48 first-in-class innovative drugs | State Council | — | 1 |
Other slices of drug approval applications
- Drug approval applications completed under priority review 2 completed · priority review
- Priority review drug approval applications completed growth rate 2 priority review
- Approved drug marketing registration applications (half year) 1 approved
Frequently asked questions
What is the latest share of priority review drug approval applications treating cancer?
China: 42.5% in 1 Jan 2020 to 20 Mar 2025.
Where does this data come from?
From 1 document published by State Council. Every figure on this page links to its record, which preserves the original source evidence.
How often is it updated?
Irregularly: the publishers behind this measure do not release it on a fixed schedule. A new figure appears here once it is published and verified.
Can I use this data?
Yes. StatOrigin publishes it under CC BY 4.0: you may copy, chart and republish it, including commercially, with attribution to StatOrigin and to the original publisher.
Cite this page
Cite the page as a data set, or open any record to cite one figure: each record carries APA, MLA, Chicago and BibTeX forms that credit the original publisher.
StatOrigin. (2026). Share of priority review drug approval applications treating cancer [Data set]. Retrieved October 28, 2026, from https://statorigin.org/indicators/share-of-priority-review-drug-approval-applications-treating-cancer
"Share of priority review drug approval applications treating cancer." StatOrigin, 2026, https://statorigin.org/indicators/share-of-priority-review-drug-approval-applications-treating-cancer. Accessed 28 Oct. 2026.
StatOrigin. "Share of priority review drug approval applications treating cancer." Data set, 2026. Accessed October 28, 2026. https://statorigin.org/indicators/share-of-priority-review-drug-approval-applications-treating-cancer.
@misc{statorigin_share_of_priority_review_drug_approval_applications_treating_cancer_2026, title = {Share of priority review drug approval applications treating cancer}, author = {{StatOrigin}}, year = {2026}, url = {https://statorigin.org/indicators/share-of-priority-review-drug-approval-applications-treating-cancer}, note = {Data set. Accessed 2026-10-28} }